Friday, The EU's drug watchdog, the European Medicines Agency (EMA), said that a review of AstraZeneca's COVID-19 vaccine found its benefits increase with age and still outweigh the risks for adults despite alleged links to blood clots.

EMA was presenting its findings after the European Commission asked it to look into concerns that prompted several countries to restrict its use to those older in age..

"It showed that the benefits of vaccination increase with increasing age and infection rates," said EMA in statements, noting the benefits outweigh its risks in adults of all age groups, despite very rare cases of blood clots with low blood platelets have occurred following vaccination.

They added that the jab is effective at preventing hospitalizations, intensive care unit admissions, and deaths from COVID-19.

The most common side effects are usually mild or moderate and get better within a few days.

Notably, the European Commission is also looking to launch legal action against AstraZeneca for underdelivering COVID-19 vaccine doses to the EU, which hobbled its early rollout.